This analysis examines the historical and forecast performance for Novartis in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Novartis's performance against key rivals in the ethical pharmaceutical sector Analyze the reasons driving Novartis's impressive forecast sales CAGR of 7.3% over the period 2006-12 Assess Novartis's late stage pipeline, the strongest within the Big Pharma peer set, which will act as the key lever on company sales growth to 2012